Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
11/2003
11/06/2003WO2003090788A1 DECOY FOR TREATING AND/OR PREVENTING Th2 CYTOKINE-ASSOCIATED ALLERGIC DISEASE, GATA3 MUTANT PROTEIN AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
11/06/2003WO2003090785A1 Methods and conpositions for treating, preventing or delaying onset of a neoplasm
11/06/2003WO2003090783A1 Preventive/remedy for diabetes
11/06/2003WO2003090782A1 Cell death inhibitor
11/06/2003WO2003090775A1 Foods and drugs containing silkworm and wild silkworm silk powder for antidementia effect and improving memorization learning
11/06/2003WO2003090770A1 Process for producing proanthocyanidine-rich material
11/06/2003WO2003090752A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003WO2003090748A1 Use of compounds having ccr antagonism
11/06/2003WO2003090743A1 Prevention and treatment of functional somatic disorders, including stress-related disorders
11/06/2003WO2003090738A1 Stress inhibition composition, theanine-containing granule and process for producing the same
11/06/2003WO2003090735A1 Therapeutic agent for inflammatory intestinal diseases containing hydroxamic acid compound as active ingredient
11/06/2003WO2003090731A1 Use of gabab receptor positive modulators in gastro-instestinal disorders
11/06/2003WO2003090728A1 Use of a mare's milk concentrate dried on a highly-dispersed, biologically inert matrix
11/06/2003WO2003090726A2 Chewable soft capsule
11/06/2003WO2003090708A1 External preparation for skin
11/06/2003WO2003090705A1 Biologically active compounds for the modification of bodily odours
11/06/2003WO2003090699A1 Cosmetic composition for promoting hair growth and/or preventing or delaying hair loss
11/06/2003WO2003090695A2 TREATMENT OF α-GALACTOSIDASE A DEFICIENCY
11/06/2003WO2003090691A2 Method and compositions for identifying anti-hiv therapeutic compounds
11/06/2003WO2003090690A2 Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such
11/06/2003WO2003090687A2 Using heat shock proteins to increase immune response
11/06/2003WO2003090681A2 SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-κB INHIBITORS AND ANTI-NEOPLASTIC AGENTS
11/06/2003WO2003090671A2 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
11/06/2003WO2003090512A2 Regeneration of endogenous myocardial tissue by induction of neovascularization
11/06/2003WO2003080125A3 Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
11/06/2003WO2003079970A3 4-(diarylmethyl)-1-piperazinyl derivatives
11/06/2003WO2003076458A3 Selective dipeptide inhibitors of kallikrein
11/06/2003WO2003075685A3 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof
11/06/2003WO2003070171A3 Myelination of congenitally dysmyelinated forebrains using oligodendrocyte progenitor cells
11/06/2003WO2003066889A3 Assay for acytyltransferase or deacetylase activity
11/06/2003WO2003062269A3 Corticotropin releasing factor receptor 2 agonists
11/06/2003WO2003057670A3 Indoles as naaladase inhibitors
11/06/2003WO2003057166A3 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003WO2003057007A3 System for monitoring bacterial tumor treatment
11/06/2003WO2003055880A3 Substituted 4-phenyltetrahydroisoquinolinium salts, method for production and use thereof as a medicament and medicaments comprising the same
11/06/2003WO2003054541A3 Inhibition of tristetraproline for protection of the heart from cardiac injuries
11/06/2003WO2003054009A3 Apoptotically active peptides
11/06/2003WO2003053999A3 Selective arylguanidine peptides as urokinase inhibitors
11/06/2003WO2003052124A3 Screening method for agents useful in treating diabetes
11/06/2003WO2003039539A3 Use of endothelin receptor antagonists in the treatment of tumour diseases
11/06/2003WO2003039455A3 Methods of treating endometreosis
11/06/2003WO2003035626A3 Azole derivatives and pharmaceutical compositions containing them
11/06/2003WO2003035005A3 Heteroindanes: a new class of potent cannabimimetic ligands
11/06/2003WO2003035004A3 Immunotherapy for reversing immune suppression
11/06/2003WO2003034900A3 Sterile, breathable patch for treating wound pain
11/06/2003WO2003032985A3 Concomitant oral and topical administration of anti - infective agents
11/06/2003WO2003031939A3 Protein modification and maintenance molecules
11/06/2003WO2003027263A3 Proteins associated with cell growth, differentiation, and death
11/06/2003WO2003018640A3 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
11/06/2003WO2003016270A3 Selective estrogen receptor modulators
11/06/2003WO2003013549A3 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals
11/06/2003WO2003007686A3 Use of copper chelators to inhibit the inactivation of protein c
11/06/2003WO2003000177A3 Stable controlled release pharmaceutical compositions containing pravastatin
11/06/2003WO2002096939A3 Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization
11/06/2003WO2002094799A3 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
11/06/2003WO2002085328A3 Method for producing an active ingredient concentrate, and an active ingredient concentrate
11/06/2003WO2002083711A3 Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
11/06/2003WO2002083083A3 Pharmaceutically active compounds and methods of use
11/06/2003WO2002076979A8 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
11/06/2003WO2002076482B1 USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS
11/06/2003WO2002070509A8 Antagonists of mcp-1 function and methods of use thereof
11/06/2003WO2002066429A8 Method for producing non-hydrated fexofenadine hydrochloride and a novel crystalline form obtained thereby
11/06/2003WO2002062945A3 Compositions and methods relating to lung specific genes and proteins
11/06/2003WO2002061105A3 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
11/06/2003WO2002060949A8 Glycoforms a fas ligand inhibitory protein analog
11/06/2003WO2002060491A3 Stabilization of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman
11/06/2003WO2002059312A3 Cell adhesion proteins
11/06/2003WO2002059117A8 Piperazine- and piperidine-derivatives as melanocortin receptor agonists
11/06/2003WO2002059108A8 Melanocortin receptor agonists
11/06/2003WO2002057489A3 Method of determining a chemotherapeutic regimen based on ercc1 and ts expression
11/06/2003WO2002053742A3 Proteins and nucleic acids encoding same
11/06/2003WO2002051983A3 Novel compounds and compositions as cathepsin inhibitors
11/06/2003WO2002044210A3 Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain
11/06/2003WO2002034204A3 Calcilytic compounds
11/06/2003WO2002032435A3 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade
11/06/2003WO2002030408A3 Compositions comprising phospholipase c inhibitors and methods for enhancing paracellular permeability across epithelial and endothelial barriers
11/06/2003WO2002024891A9 B7-like molecules and uses thereof
11/06/2003WO2002018369A8 Peptidomimetic protease inhibitors
11/06/2003WO2002009639A3 Methods and pharmaceutical compositions for healing wounds
11/06/2003WO2002005749A3 Crf2 ligands in combination therapy
11/06/2003WO2002002096A8 Oral compositions comprising host-response modulating agent
11/06/2003WO2001080633A8 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
11/06/2003WO2000033865A8 Methods of inhibiting ectopic calcification
11/06/2003US20030208780 Useful in preparing recombinant cells for diagnosis and therapy of human tumors
11/06/2003US20030208084 Sulfonamides and derivatives thereof that modulate the activity of endothelin
11/06/2003US20030208082 Nitrogen compounds such as 4,5-diisopropyl-1-methyl-2-styryl -1H-imidazole, used as glutamate receptor antagonists, for prophylaxis of psychological disorders, as anxiolytic agents and analgesics
11/06/2003US20030208079 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for proph7ylaxis of cardiovascular disorders
11/06/2003US20030208076 Preparation of fused polycyclic alkaloids by ring closure of azomethine ylides, novel compounds thereof and their use as chemotherapeutic agents
11/06/2003US20030208067 Inhibitors of protein kinase for the treatment of disease
11/06/2003US20030208059 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
11/06/2003US20030208058 B7-like polypeptides and polynucleotides
11/06/2003US20030208048 Anti-alphavbeta3 recombinant human antibodies, nucleic acids encoding same and methods of use
11/06/2003US20030208046 Pseudo native chemical ligation
11/06/2003US20030207944 Aminotetralin derivative for the therapy of cardiovascular diseases
11/06/2003US20030207937 Such as ethyl-2,2-4,4-tetramethyl-chroman-6-carboxylate; for retinoid-treatable conditions
11/06/2003US20030207936 Comprises fatty ester modified-polyoxyethylene glycol solubilizers
11/06/2003US20030207931 Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1h-1,2,4-triazole for the treatment of autoimmune diseases
11/06/2003US20030207930 Valsartan salts
11/06/2003US20030207925 Methods of treatment with selective EP4 receptor agonists
11/06/2003US20030207924 Compounds that modulate PPAR activity and methods of preparation
1 ... 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 ... 1564